Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study
Standard
Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. / Mathieu, Romain; Klatte, Tobias; Lucca, Ilaria; Beutcha, Aurélie M; Seitz, Christian; Karakiewicz, Pierre I; Fajkovic, Harun; Sun, Maxine; Lotan, Yair; Scherr, Douglas S; Montorsi, Francesco; Briganti, Alberto; Rouprêt, Morgan; Margulis, Vitaly; Rink, Michael; Kluth, Luis A; Rieken, Malte; Kenner, Lukas; Susani, Martin; Robinson, Brian D; Xylinas, Evanguelos; Loidl, Wolgang; Shariat, Shahrokh F.
in: BJU INT, Jahrgang 118, Nr. 2, 01.08.2016, S. 243-9.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study
AU - Mathieu, Romain
AU - Klatte, Tobias
AU - Lucca, Ilaria
AU - Beutcha, Aurélie M
AU - Seitz, Christian
AU - Karakiewicz, Pierre I
AU - Fajkovic, Harun
AU - Sun, Maxine
AU - Lotan, Yair
AU - Scherr, Douglas S
AU - Montorsi, Francesco
AU - Briganti, Alberto
AU - Rouprêt, Morgan
AU - Margulis, Vitaly
AU - Rink, Michael
AU - Kluth, Luis A
AU - Rieken, Malte
AU - Kenner, Lukas
AU - Susani, Martin
AU - Robinson, Brian D
AU - Xylinas, Evanguelos
AU - Loidl, Wolgang
AU - Shariat, Shahrokh F
N1 - © 2015 The Authors BJU International © 2015 BJU International Published by John Wiley & Sons Ltd.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - OBJECTIVE: To validate Caveolin-1 as an independent prognostic marker of biochemical recurrence (BCR) in a large multi-institutional cohort of patients with prostate cancer treated with radical prostatectomy (RP).PATIENTS AND METHODS: Caveolin-1 expression was evaluated by immunochemistry on a tissue microarray in 3 117 patients treated with RP for prostate cancer at five institutions. Univariable and multivariable Cox proportional hazards regression models assessed the association of Caveolin-1 status with BCR. Harrell's c-index quantified prognostic accuracy.RESULTS: Caveolin-1 was overexpressed in 644 (20.6%) patients and was associated with higher pathological Gleason sum (P = 0.002) and lymph node metastases (P = 0.05). Within a median (interquartile range) follow-up of 38 (21-66) months, 617 (19.8%) patients experienced BCR. Patients with overexpression of Caveolin-1 had worse BCR-free survival than those with normal expression (log-rank test, P = 0.004). Caveolin-1 was an independent predictor of BCR in multivariable analyses that adjusted for the effects of standard clinicopathological features (hazard ratio 1.21, P = 0.037). Addition of Caveolin-1 in a model for prediction of BCR based on these standard prognosticators did not significantly improve the predictive accuracy of the model. In subgroup analyses, Caveolin-1 was associated with BCR in patients with favourable pathological features (pT2pN0 and Gleason score = 6; P = 0.021).CONCLUSIONS: We confirmed that overexpression of Caveolin-1 is associated with adverse pathological features in prostate cancer and independently predicts BCR after RP, especially in patients with favourable pathological features. However, it did not add prognostically relevant information to established predictors of BCR, limiting its use in clinical practice.
AB - OBJECTIVE: To validate Caveolin-1 as an independent prognostic marker of biochemical recurrence (BCR) in a large multi-institutional cohort of patients with prostate cancer treated with radical prostatectomy (RP).PATIENTS AND METHODS: Caveolin-1 expression was evaluated by immunochemistry on a tissue microarray in 3 117 patients treated with RP for prostate cancer at five institutions. Univariable and multivariable Cox proportional hazards regression models assessed the association of Caveolin-1 status with BCR. Harrell's c-index quantified prognostic accuracy.RESULTS: Caveolin-1 was overexpressed in 644 (20.6%) patients and was associated with higher pathological Gleason sum (P = 0.002) and lymph node metastases (P = 0.05). Within a median (interquartile range) follow-up of 38 (21-66) months, 617 (19.8%) patients experienced BCR. Patients with overexpression of Caveolin-1 had worse BCR-free survival than those with normal expression (log-rank test, P = 0.004). Caveolin-1 was an independent predictor of BCR in multivariable analyses that adjusted for the effects of standard clinicopathological features (hazard ratio 1.21, P = 0.037). Addition of Caveolin-1 in a model for prediction of BCR based on these standard prognosticators did not significantly improve the predictive accuracy of the model. In subgroup analyses, Caveolin-1 was associated with BCR in patients with favourable pathological features (pT2pN0 and Gleason score = 6; P = 0.021).CONCLUSIONS: We confirmed that overexpression of Caveolin-1 is associated with adverse pathological features in prostate cancer and independently predicts BCR after RP, especially in patients with favourable pathological features. However, it did not add prognostically relevant information to established predictors of BCR, limiting its use in clinical practice.
U2 - 10.1111/bju.13224
DO - 10.1111/bju.13224
M3 - SCORING: Journal article
C2 - 26189876
VL - 118
SP - 243
EP - 249
JO - BJU INT
JF - BJU INT
SN - 1464-4096
IS - 2
ER -
